Recurv Pharma

Recurv Pharma is a biopharmaceutical company focused on developing next-generation oncology treatments for solid tumors. The company's lead program, RP-001, is a novel taxane therapy delivered via a proprietary oil-in-water nano-emulsion formulation designed to target tumors specifically while sparing healthy tissue. RP-001 has demonstrated the ability to kill cancer stem cells and overcome multi-drug resistance in various preclinical models, including pancreatic, lung, and breast cancers. Recurv is a project-focused company (PFC) backed by TVM Capital Life Science and operates in collaboration with Eli Lilly’s Chorus unit to advance its candidate through clinical proof-of-concept.